



**Testimony in Favor of Senate Bill 987
Before the Senate Budget and Taxation Committee
By Vincent DeMarco,
President, Maryland Citizens' Health Initiative
March 11, 2026**

Chair Guzzone, Vice Chair Rosapepe, and Members of the Budget and Taxation Committee;

Thank you for the opportunity to testify on Senate Bill 987. I am submitting this testimony on behalf of our individual organization, Maryland Citizens' Health Initiative, as we have not yet reviewed this bill with the full Maryland Health Care for All Coalition. Because this legislation will help meet critical health care needs in our state, we strongly urge you to give SB 987 a favorable report. Thank you very much to Senator Karen Lewis Young for sponsoring it.

Under your Committee's leadership we have made great gains in Maryland in expanding access to quality, affordable health care for all Marylanders. Since the passage of the Affordable Care Act (ACA) we have gone from 13% of Marylanders being uninsured to 6%. Keeping Marylanders insured ultimately helps all of us because when Marylanders lose their health coverage, they often have to get their care in the emergency room which is the most expensive place possible. The resulting uncompensated care drives up everyone's health insurance premiums. Expanding access to health coverage in Maryland has resulted in [\\$460 million in savings](#) to the health care system which helped stabilize premiums for everybody.

However, in the coming years hundreds of thousands of Marylanders could lose their coverage due to new administrative burdens and budget cuts from HR 1 and Congress's termination of enhanced advance premium tax credits. The resulting uncompensated care will cause everyone's health insurance premiums to rise. None of us can afford for Marylanders to lose coverage.

SB 987 would combat federal attacks on Marylanders' access to health coverage, and help keep people covered. Under HR 1 there will be new work requirements and six-month redeterminations for adults who receive Medicaid through the ACA expansion. We know from examples in other states that work requirements don't increase employment. In Maryland the vast majority of Medicaid recipients are already working or have a reason not to be like going to school or serving as a caregiver or having a disability, but the added administrative burden could cause them to fall off their Medicaid coverage, ironically making it less likely that people will be able to stay healthy enough to work.

SB 987 would put \$5 million per year into funding Medicaid eligibility operations, which would help the State build and maintain the infrastructure to keep Marylanders from falling through the cracks and losing their Medicaid coverage. Investing in IT systems to use the data the state already has to verify eligibility can simplify the enrollment and re-enrollment process for Medicaid participants and state employees alike. Navigators, working in local communities across the state, were critical in helping Marylanders get enrolled in health coverage during the rollout of the ACA. Using this successful strategy again by investing in navigators in local health departments can help prevent Marylanders from losing coverage due to the new administrative

requirements and provide individualized support. Investing in eligibility operations reduces the risk that people will lose coverage due to paperwork issues.

SB 987 would put funds above \$5 million into premium assistance programs that Maryland Health Benefit Exchange would use to protect Marylanders' access to coverage. Due to Congress's termination of enhanced premium tax credits, many Marylanders who purchase private health coverage from Maryland Health Benefit Exchange are experiencing spiking health insurance premium costs, or are at risk for higher costs in the future. In 2025 Maryland wisely created the State Based Individual Subsidy Program to mitigate enrollment losses and stabilize the marketplace. This builds on the Young Adult Subsidy Program which has been in place since 2022 and helps stabilize the marketplace by bringing younger and healthier Marylanders into the marketplace. These programs have been lifesavers for Marylanders to be able to continue to afford their coverage. However, these programs are at risk due to lack of future funding. If they shrink or are discontinued even more Marylanders will lose their ability to pay for health insurance.

As one of only two countries that allows direct-to-consumer pharmaceutical advertising, the United States is an outlier. These ads, which are largely viewed as a public annoyance to television audiences, can actually do harm by driving up health care costs and compromising provider-patient relationships. With over [\\$14 billion spent in a single year](#) on these advertisements, tax-payers are footing the bill for patients to be flooded with unwanted, repeated exposure to marketing for prescription drugs they may not be able to afford. Senate Bill 987 is an innovative way to address this issue, protecting consumers from the skyrocketing cost of prescription drugs while also generating revenue to help support the growing health care coverage demands of our state. This legislation mirrors [federal efforts](#) to eliminate tax deductions for direct-to-consumer advertisement by pharmaceutical manufacturers, which is expected to [increase federal tax revenue by \\$1.5-1.7 billion annually](#). If scaled down to represent similar metrics at a state level, Maryland could see tens of millions of dollars in increased revenue.

We thank Senator Karen Lewis Young and Delegate Natalie Ziegler for their leadership on this issue and wholeheartedly support the ongoing effort to put patients over Big Pharma profits. For too long, the pharmaceutical industry has claimed they need to keep their prices high for research and development while they have [spent many times more on advertising and self-enriching activities](#). (Report by Public Citizen attached) It is time that Maryland puts an end to taxpayer sponsorship of this practice and puts our patients first. Please protect the progress that we as a state have made expanding access to quality, affordable health care for all Marylanders.

We thank the Committee for your consideration of this legislation and urge a favorable report on Senate Bill 987.

PROFITS OVER PATIENTS

Spending on Self-Enrichment Exceeds Research and Development Costs for Many Manufacturers of IRA Drugs

By Jishian Ravinthiran

January 18, 2024

PROTECT
OUR CARE



ACKNOWLEDGMENTS

This report was written by Jishian Ravinthiran in Public Citizen’s Access to Medicine’s Program. Alan Zibel, Megan Whiteman, and Peter Maybarduk edited the report.

ABOUT PUBLIC CITIZEN

Public Citizen is a national nonprofit organization with more than 500,000 members and supporters. We represent consumer interests through lobbying, litigation, administrative advocacy, research, and public education on a broad range of issues including consumer rights in the marketplace, product safety, financial regulation, worker safety, safe and affordable health care, campaign finance reform and government ethics, fair trade, climate change, and corporate and government accountability.

ABOUT PROTECT OUR CARE

Protect Our Care is dedicated to making high-quality, affordable, and equitable health care a right, and not a privilege, for everyone in America. We educate the public, influence policy, support health care champions and hold politicians accountable.

Contact Public Citizen

Main Office
1600 20th St. NW
Washington, DC 20009

Capitol Hill
215 Pennsylvania Ave. SE, #3
Washington, DC 20003

Texas Office
309 E. 11th St., Suite 2
Austin, TX 78701

Phone: (202) 588-1000

Phone: (202) 546-4996

Phone: (512) 477-1155

For more information, please visit www.citizen.org.



Executive Summary

The federal and state governments are taking significant steps to deliver much-needed drug pricing relief to millions of Americans. Measures include a historic provision in the Inflation Reduction Act allowing Medicare to negotiate prices for select drugs, draft executive guidance to license generic competition on taxpayer funded drugs, and state Prescription Drug Affordability Boards with the power to limit expenditures on drugs. But as governments rise to the challenge of tackling the decades long problem of excessive drug prices, the pharmaceutical industry raises significant opposition to insulate its profiteering from popular measures. Chief among their claims is that regulating drug prices will reduce industry profits, and thus capacity to invest in the research and development of new medicines. But that claim is belied by these corporations' own expenditures on self-enriching activities, including stock buybacks, dividends to shareholders, and executive compensation, that far exceed their investments in innovation.

- The manufacturers of the first 10 drugs selected for Medicare price negotiation, in aggregate, spent \$10 billion more on self-enriching activities than on research and development in 2022.
- For manufacturers of the 10 drugs with the highest expenditures by Maryland payers, including Medicare, Medicaid, and certain commercial insurance plans, companies spent \$9 billion more on stock buybacks, dividends, and executive compensation than on research and development expenses in 2022.
- Executive compensation for the manufacturers of the drugs selected for Medicare price negotiation exceeded half a billion dollars in just 2022. The same is true for executive compensation for the manufacturers of the 10 costliest drugs in Maryland. Most of this compensation is keyed to stock prices, which incentivizes short-term measures to inflate share prices, such as stock buybacks, rather than long-term investments in researching and developing new drugs.

Introduction

Price gouging on essential medicines harms the health of millions of Americans every year. In 2021, approximately 9.2 million Americans were unable to take medications as prescribed due to costs.¹ People with disabilities were three times more likely to be unable to take medications as prescribed due to these cost barriers.² Nearly one in four uninsured Americans skipped doses, took less medication, or delayed filling a prescription because of costs.³ Data from 2023 shows that three in ten Americans have not taken their medications as prescribed due to costs, 82% of Americans say the cost of prescription drugs is unreasonable, and 73% say that the government is not doing enough to regulate drug prices.⁴

Considering this drug pricing crisis, the federal and state governments have taken significant steps to make high-cost drugs more affordable and deliver relief for patients everywhere. Several states, starting with Maryland in 2019, have established Prescription Drug Affordability Boards, which are charged with analyzing the excessive costs of prescription drugs and identifying solutions to medicine inaccessibility. Four of these states—Colorado, Maryland, Minnesota, and Washington—have empowered their Boards to set upper payment limits for the purchase of certain prescription drugs.⁵ At the federal level, Congressional Democrats passed and President Biden signed into law the Inflation Reduction Act, which includes a provision allowing Medicare Part D to negotiate the price of select drugs for the first time in the program’s 20-year history.⁶ The law also capped the out-of-pocket costs for insulin at \$35 per month for Medicare enrollees and annual out-of-pocket expenses for prescription drugs at \$2,000.⁷ More recently, the Biden administration announced draft guidance that would empower federal agencies to license

¹ Laryssa Mykyta, and Robin A. Cohen, Centers for Disease Control and Prevention, National Center for Health Statistics, *Characteristics of Adults Aged 18–64 Who Did Not Take Medication as Prescribed to Reduce Costs: United States, 2021*, NCHS DATA BRIEF NO. 470 (June 2023).

² *Id.* at 2.

³ *Id.* at 3.

⁴ Ashley Kirzinger, Alex Montero, Grace Sparks, Isabelle Valdes, & Liz Hamel, *Public Opinion Prescription Drugs and Their Prices*, KFF (Aug. 21, 2023), <https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-and-their-prices/>.

⁵ See e.g., CO. Senate Bill 21-175, Sec. 10-16-1407; Md. Code, Health-Gen. § 21-2C-14; Minn. Sess. L. 2023 Ch. 57, art. 2, Sec. 35; Rev. Code Wash. 70.405.050.

⁶ The White House, *FACT SHEET: Biden-Harris Administration Announces First Ten Drugs Selected for Medicare Price Negotiation*, STATEMENTS & RELEASES (Aug. 29, 2023), <https://www.whitehouse.gov/briefing-room/statements-releases/2023/08/29/fact-sheet-biden-harris-administration-announces-first-ten-drugs-selected-for-medicare-price-negotiation/>.

⁷ Centers for Medicare & Medicaid, *Anniversary of the Inflation Reduction Act: Update on CMS Implementation*, CMS.GOV (Aug. 16, 2023), <https://www.cms.gov/newsroom/fact-sheets/anniversary-inflation-reduction-act-update-cms-implementation>.

generic competition to make taxpayer-funded medicines more affordable where drug manufacturers price the medicine excessively.⁸

The pharmaceutical industry has been staunchly opposed to popular reforms designed to constrain their unreasonable profiteering on medicines. The industry has criticized Prescription Drug Affordability Boards, the Inflation Reduction Act's provisions on price negotiation, and the Biden administration's framework for licensing generic competition on taxpayer funded medicines, with most concerns being funneled into the claim that any attempts to rein in their price-gouging tactics will impact the research and development of new medicines.⁹

That claim is flawed for several reasons. First, researchers and the Congressional Budget Office conclude there is no connection between a drug's research and development cost and its future price.¹⁰ Rather, the current price of drugs reflects what companies believe the market will bear in response to their monopolistic pricing power.¹¹ Second, compared to the rest of the globe, the United States is an outlier that does little to protect its residents from the unfair pricing power of drug companies,¹² and bringing American policy into alignment with those of other countries, including other high-income peers, will not destroy the incentive to innovate new medicines.

⁸ NIST Releases for Public Comment Draft Guidance on March-In Rights, <https://www.nist.gov/news-events/news/2023/12/nist-releases-public-comment-draft-guidance-march-rights> (last visited Dec. 12, 2023).

⁹ See PhRMA, *States Can Help Patients Pay Less for Their Medicines*, STATE POLICIES AND ISSUES, <https://phrma.org/en/States> (last visited Jan. 11, 2023); PhRMA, INFLATION REDUCTION ACT'S UNINTENDED CONSEQUENCES, https://phrma.org/inflation-reduction-act?utm_campaign=2024-q1-pri-v6&utm_medium=pai_srh_cpc-ggl-adf&utm_source=ggl&utm_content=clk-pat-v6-v6-v6-all-pai_srh_cpc-ggl-adf-IRAEvergreenSearchWCNational1-evg-v6-v6-lrm-soc_txt-v6-vra-ADF&utm_term=inflation%20reduction%20act&utm_campaign=&utm_source=adwords&utm_medium=ppc&hsa_acc=8523309176&hsa_cam=20882819512&hsa_grp=158617381844&hsa_ad=685220095153&hsa_src=g&hsa_tgt=kwd-1705916798609&hsa_kw=inflation%20reduction%20act&hsa_mt=b&hsa_net=adwords&hsa_ver=3&gad_source=1&gclid=Cj0KCOiAwP6sBhDAARIsAPfK_wZ3PhDU-6cvBxNUI9JVXtfl-nZch3LOEQIJOA2j_rY2LRRBqHdL7fOaAkKjEALw_wcB (last visited Jan. 11, 2024); PhRMA Statement on Proposed March-In Framework, PhRMA (Dec. 6, 2023), <https://phrma.org/resource-center/Topics/Access-to-Medicines/PhRMA-Statement-on-Proposed-March-In-Framework>.

¹⁰ CONGRESSIONAL BUDGET OFFICE, RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY (Aug. 2021) ("In CBO's assessment, current R&D spending does not influence the future prices of the drugs that result from that spending."); Aaron Kesselheim, Jerry Avorn, & Ameet Sarpatwari, *The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform*, 316 JAMA NETWORK 858 (2016); Vinay Prasad, Kevin De Jesus, Sham Mailankody, *The high price of anticancer drugs: origins, implications, barriers, solutions*, 14 NAT. REV. CLIN. ONC. 381 (2016).

¹¹ Aaron Kesselheim, Jerry Avorn, & Ameet Sarpatwari, *The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform*, 316 JAMA NETWORK 858 (2016).

¹² Amy Kapczynski, *The Political Economy of Market Power in Pharmaceuticals*, 48 J. HEALTH POL., POL'Y & L. 215 (2023); S. Vincent Rajkumar, *The high cost of prescription drugs: causes and solutions*, 10 BLOOD & CANCER J. 381 (2020).

Finally, as this report will emphasize, pharmaceutical companies spend in excess on executive compensation, share buybacks, and dividends which enrich their shareholders, cutting against the industry's mistaken impression that it is strapped for resources to research and develop new medicines.¹³ Stock buybacks enrich investors by reducing the number of outstanding shares in a company. The fewer shares there are in investors' hands, the more each share is worth. When a company buys back and cancels 10% of its shares, that makes each share still held by an investor or insider rise in value, as it represents a greater claim on the company's earnings. Spending money this way allows companies to enrich shareholders silently, as well as the executives often paid in stock.¹⁴ Dividends are another way of returning cash to investors. Each fiscal quarter, publicly traded companies typically issue fixed dividends to shareholders that rise when business is good and shrink or get suspended when business is bad.¹⁵ Drug companies spend billions on stock buybacks and dividends to shareholders each year.¹⁶

A recent report by Protect Our Care shows that the drug companies marketing the drugs selected for the first round of Medicare price negotiation under the Inflation Reduction Act spent approximately \$20 billion on stock buybacks and \$54 billion on dividends to shareholders in 2023 as of November.¹⁷ These excessive expenditures on share buybacks and dividends were also highlighted in a 2021 Drug Pricing Report from the House Oversight & Reform Committee, which found the industry argument "that permitting Medicare to negotiate drug prices would stifle innovation is not supported by available evidence or findings from the Committee's multi-year investigation into the pharmaceutical industry."¹⁸ The investigation found that 14 large pharmaceutical companies spent \$56 billion more on stock buybacks and dividends compared to research and development expenditures between 2016 and 2020.¹⁹

This report by Public Citizen and Protect Our Care highlights those findings and recenters the lavish expenditures of the manufacturers of the first 10 prescription drugs selected for Medicare price negotiations as industry renews claims that drug pricing relief will harm innovation. This report also examines the self-enriching activities of the manufacturers of

¹³ Amy Kapczynski, *The Political Economy of Market Power in Pharmaceuticals*, 48 J. HEALTH POL., POL'Y & L. 215, 230 (2023) (citing Aaron Kesselheim & Jeffrey Avorn, *Letting the Government Negotiate Drug Prices Won't Hurt Innovation*, WASH. POST (Sept. 27, 2021), <https://www.washingtonpost.com/outlook/2021/09/22/drug-pricing-negotiation-biden-bill/>); U.S. HOUSE OF REPRESENTATIVES' COMMITTEE ON OVERSIGHT & REFORM, DRUG PRICING INVESTIGATION: INDUSTRY SPENDING ON BUYBACKS, DIVIDENDS, & EXECUTIVE COMPENSATION (July 2021).

¹⁴ PUBLIC CITIZEN, BAILOUT WATCH, FRIENDS OF THE EARTH, BIG OIL'S WARTIME BONUS 2 (2022).

¹⁵ *Id.* at 8.

¹⁶ PROTECT OUR CARE, GREED WATCH: BIG COMPANIES CONTINUE TO BRING IN BILLIONS WHILE AMERICANS STRUGGLE TO AFFORD SKYROCKETING PRICES 4 (Nov. 2023), [GREED-WATCH-Big-Drug-Companies-Continue-To-Bring-In-Hundreds-of-Billions-While-Americans-Struggle-To-Afford-Skyrocketing-Prices.pdf](https://www.protectourcare.org/wp-content/uploads/2023/11/Greed-Watch-Big-Drug-Companies-Continue-To-Bring-In-Hundreds-of-Billions-While-Americans-Struggle-To-Afford-Skyrocketing-Prices.pdf) ([protectourcare.org](https://www.protectourcare.org)).

¹⁷ *Id.*

¹⁸ U.S. HOUSE OF REPRESENTATIVES' COMMITTEE ON OVERSIGHT & REFORM, DRUG PRICING INVESTIGATION: INDUSTRY SPENDING ON BUYBACKS, DIVIDENDS, & EXECUTIVE COMPENSATION 11 (JULY 2021).

¹⁹ *Id.* at 3.

the 10 drugs with the highest expenditures by payers in Maryland, which was the first state to establish a Prescription Drug Affordability Board. As other states consider passing similar legislation to create Prescription Drug Affordability Boards,²⁰ and as advocates in Maryland press for the expansion of its Board's upper payment limit authority to help more residents,²¹ this report shows that the expenditures for the costliest drugs at the state level mirror the excessive spending on self-enrichment at the national level. Ultimately, the data shows these companies are not strapped for resources: they spend billions more on executive compensation, stock buybacks, and dividends to shareholders than research and development activities.

²⁰ Drew Gattine & Jennifer Reck, *State House Wrap-Up: States Continue to Tackle High Prices in 2023 Session*, NAT. ACAD. STATE HEALTH POL'Y BLOG (Oct. 30, 2023), <https://nashp.org/state-house-wrap-up-states-continue-to-tackle-high-drug-prices-in-2023-session/>.

²¹ Daniel J. Brown, *Health care legislation preview: Maryland advocates want to focus on access, patients in 2024 session*, MARYLAND MATTERS (Jan. 8, 2024), <https://www.marylandmatters.org/2024/01/08/health-care-legislation-preview-maryland-advocates-want-to-focus-on-access-patients-in-2024-session/>.

Manufacturers of the Drugs Selected for Medicare Price Negotiation Spent Billions More on Dividends, Stock Buybacks, and Executive Compensation than Research & Development

In August 2023, the Biden administration announced the first 10 drugs selected for Medicare price negotiation under the Inflation Reduction Act.²² Between June 2022 and May 2023, these ten drugs cost Medicare Part D \$50.5 billion.²³ The manufacturers of the drugs and relevant financial information obtained from Form 10-K, 20-F, and proxy statement filings with the Securities Exchange Commission (SEC), and publicly available accounting statements are listed in Table 1. Detailed methodology for all tables is contained in the Appendix. For example, Johnson & Johnson (JNJ) spent \$11.682 billion on dividends to shareholders, \$6.035 billion on stock buybacks, and \$45 million on executive compensation in 2022. In total, JNJ spent \$17.762 billion on these self-enriching activities compared to \$14.6 billion on research and development.

In aggregate, the manufacturers of the drugs selected for Medicare price negotiation spent \$10 billion more on stock buybacks, dividends, and executive compensation than research and development in 2022. If the \$12 billion in advertising expenditures are also included to show the significant resources at these companies' disposal, manufacturers of drugs selected for Medicare price negotiation spent \$22 billion more compared to research and development expenses.²⁴

²² *HHS Selects the First Drugs for Medicare Drug Price Negotiation*, HHS.GOV (Aug. 23, 2023), <https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html>.

²³ *Id.*

²⁴ Manufacturers of the first drugs selected for Medicare negotiation spent 12.241 on advertising according to disclosures in Form 10-K filings with the SEC.

Table 1: Spending by Manufacturers of Drugs Selected for Medicare Price Negotiation (in dollars)

Drug Company	Drug Name	Dividends	Stock Buybacks	Exec. Comp.	Dividends, Stock Buybacks, & Exec. Comp.	R&D
AbbVie	Imbruvica	10.043 billion	1.487 billion	71.91 million	11.602 billion	6.510 billion
Amgen	Enbrel	4.196 billion	6.360 billion	50.25 million	10.606 billion	4.434 billion
AstraZeneca	Farxiga	4.364 billion	--	22.27 million	4.386 billion	9.762 billion
BMS	Eliquis	4.634 billion	8.001 billion	48.04 million	12.683 billion	9.509 billion
Pfizer	Eliquis	8.983 billion	2.000 billion	107.23 million	11.090 billion	11.428 billion
JNJ	Stelara, Xarelto, Imbruvica	11.682 billion	6.035 billion	45.19 million	17.762 billion	14.603 billion
Bayer AG	Xarelto	2.087 billion	--	23.26 million	2.111 billion	6.911 billion
Merck	Januvia	7.012 billion	--	60.46 million	7.072 billion	13.548 billion
Novartis	Entresto	7.506 billion	10.652 billion	51.75 million	18.210 billion	9.996 billion
Novo Nordisk	Fiasp/ Novolog	3.575 billion	3.403 billion	36.84 million	7.016 billion	3.398 billion
Eli Lilly	Jardiance	3.536 billion	1.500 billion	44.48 million	5.080 billion	7.191 billion
Total		67.619 billion	39.438 billion	561.68 million	107.619 billion	97.290 billion

As shown in Table 2, executive compensation for these manufacturers exceeded half a billion dollars in just one year. More than half of executive compensation was based on equity awards, thereby directly linking executive pay to share price. The payment structure incentivizes share repurchases to inflate stock values, which increases executive compensation in the short-term.


Table 2: Executive Compensation for the Manufacturers of Drugs Selected for Medicare Price Negotiation (in dollars)

Drug Company	Drug(s) selected for Negotiation	Number of Corporate Officers	Executive Base Pay	Equity-Based Awards	Total Compensation
AbbVie	Imbruvica	6	7,041,609	46,525,585	71,913,444
Amgen	Enbrel	5	6,051,861	34,111,067	50,245,442
AstraZeneca	Farxiga	2	2,765,721	13,000,000	22,266,338
BMS	Eliquis	5	6,055,263	31,506,942	48,038,921
Pfizer	Eliquis	6	7,768,166	48,970,106	107,228,894
JNJ	Stelara, Xarelto, Imbruvica	5	5,409,809	32,034,706	45,186,672
Bayer AG	Xarelto	6	6,661,409	4,413,249	23,263,933
Merck	Januvia	6	6,063,476	39,967,603	60,463,107
Novartis	Entresto	16	11,423,342	21,563,333	51,753,687
Novo Nordisk	Fiasp/Novolog	10 ²⁵	11,374,876	14,893,316	36,837,643
Eli Lilly	Jardiance	5	5,258,655	31,193,250	44,477,379
Total		72	75,874,187	318,179,157	561,675,460

In sum, these figures suggest that these drug corporations have ample resources to invest in research and development, which belies industry claims that the Medicare price negotiation provisions will stifle innovation.

²⁵ According to Novo Nordisk's Remuneration Report 2022, there is a category for non-registered executives, which includes 3 named persons. It remains unclear if other individuals are included in this category as well.

Figure 1: Spending by Manufacturers of Drugs Selected for Medicare Price Negotiation (in Billions of Dollars)



Manufacturers of the Costliest Drugs in Maryland Spent Billions More on Dividends, Stock Buybacks, and Executive Compensation than Research & Development

A similar pattern of corporate enrichment emerges for the 10 costliest drugs in Maryland. In 2022, Maryland’s Prescription Drug Affordability Board published a report that detailed the 10 drugs payers, including Medicare, Medicaid, and certain commercial insurance plans, spent the most on in 2019.²⁶ The manufacturers of those drugs and their respective spending on dividends, stock buybacks, executive compensation, and research and development are reported in Table 3 using securities filings and publicly available statements. These drug corporations spent \$9 billion more on share repurchases, dividends to shareholders, and executive compensation than on research and development in 2022. When the \$10 billion in advertising expenditures are included to illustrate the lack of resource constraints facing these companies, pharmaceutical manufacturers of the 10 costliest drugs in Maryland spent \$19 billion more compared to research and development expenses.²⁷

²⁶ MARYLAND PRESCRIPTION DRUG AFFORDABILITY BOARD, SECTION 21-2C-09(c) (2022) ANNUAL COST REVIEW REPORT 7 (Dec. 31, 2022).

²⁷ Manufacturers of the 10 costliest drugs in Maryland spent 10.032 billion on advertising expenses in 2022 according to disclosures in Form 10-K filings with the SEC.

PUBLIC CITIZEN

Table 3: Spending by the Manufacturers of the Costliest Drugs in Maryland (in dollars)

Drug Company	Drug Name	Dividends	Stock Buybacks	Exec. Comp.	Dividends, Stock Buybacks, & Executive Compensation	R&D
AbbVie	Humira	10.043 billion	1.487 billion	71.91 million	11.602 billion	6.510 billion
Gilead	Biktarvy, Genvoya	3.709 billion	1.396 billion	53.12 million	5.158 billion	4.977 billion
BMS	Eliquis	4.634 billion	8.001 billion	48.04 million	12.683 billion	9.509 billion
GSK	Triumeq ²⁸	4.275 billion	--	25.85 million	4.301 billion	6.767 billion
Pfizer	Triumeq, Eliquis	8.983 billion	2.000 billion	107.23 million	11.090 billion	11.428 billion
Shionogi ²⁹	Triumeq	.275 billion	.377 billion	3.93 million	.656 billion	.569 billion
Biogen	Tecfidera	--	.750 billion	86.51 million	0.837 billion	2.231 billion
Eli Lilly	Trulicity	3.536 billion	1.500 billion	44.48 million	5.080 billion	7.191 billion
JNJ	Stelara	11.682 billion	6.035 billion	45.19 million	17.762 billion	14.603 billion
Novo Nordisk	Fiasp/ Novolog	3.575 billion	3.403 billion	36.84 million	7.016 billion	3.398 billion
Total		50.712 billion	24.949 billion	523.09 million	76.185 billion	67.183 billion

²⁸ Triumeq is marketed by Viiv Healthcare, which is a joint venture between Pfizer, GSK, and Shionogi.

²⁹ Shionogi is a Japanese company that operates on a fiscal year from April 1, 2022 through March 31, 2023. Instead, data for this company on stock buybacks, dividends, and research and development was taken for April 1, 2022 through December 31, 2022 (9 months). However, executive compensation figures are only available on a yearly basis, so that information is taken from the 2022 report spanning April 1, 2022 through March 31, 2023.


Like the manufacturers of the drugs selected for Medicare price negotiation, manufacturers of the ten costliest drugs in Maryland spent over half a billion dollars on executive compensation in just 2022 (see Table 4). For these companies, 60% of executive pay was based on equity awards, helping drive corporate investment in short-term measures to inflate stock values, such as stock buybacks, as opposed to long-term investments in research and development.

Table 4: Executive Compensation for the Manufacturers of the Costliest Drugs in Maryland (in dollars)

Drug Company	Drug Name	Number of Officers	Base Pay	Equity-Based Compensation	Total Compensation
AbbVie	Humira	6	7,041,609	46,525,585	71,913,444
Gilead	Biktarvy, Genvoya	5	5,244,613	34,198,123	53,120,567
BMS	Eliquis	5	6,055,263	31,506,942	48,038,921
GSK	Triumeq	3	4,324,291	12,208,385	25,850,801
Pfizer	Triumeq	6	7,768,166	48,970,106	107,228,894
Shionogi	Triumeq	5	1,574,695	958,510	3,925,327
Biogen	Tecfidera	7	5,184,996	66,506,517	86,506,118
Eli Lilly	Trulicity	5	5,258,655	31,193,250	44,477,379
JNJ	Stelara	5	5,409,809	32,034,706	45,186,672
Novo Nordisk	Fiasp/Novolog	10	11,374,876	14,893,316	36,837,643
Total		57	59,236,974	318,995,440	523,085,767

In sum, establishing state Prescription Drug Affordability Boards with the authority to limit the price of drug transactions or expanding these boards' authority to deliver relief to more residents does not constrain industry capacity to invest in drug innovation. Drug companies of the costliest drugs in states, which are often the manufacturers of the costliest drugs nationally, have significant resources to invest in research and development.

Figure 2: Spending by Manufacturers of the Costliest Drugs in Maryland (in Billions of Dollars)



Conclusion

Supermajorities of Americans believe that drug prices are unreasonable and that the government is doing too little to protect its residents from their excessive costs. As federal and state governments rise to the occasion and deliver relief from the price-gouging of their constituents, it is expected that the pharmaceutical industry will raise strong opposition to these efforts to preserve their profiteering. Most commonly, opposition to popular relief centers the claim that reducing their profits in any manner will constrain their resources to invest in new medicines.

As experts, advocates, scholars, and government oversight institutions have reiterated for years, those claims are belied by the lavish expenditures of these companies on activities to enrich their shareholders and executives, which outweigh their investment in the innovation of new drugs. Indeed, this rings true for the corporations manufacturing the first drugs selected for Medicare price negotiation and the costliest drugs in Maryland, with billions spent in excess of research and development expenses on dividends, stock buybacks, and executive compensation. As such, there is no necessary relationship between drug pricing relief for millions and harming resources for innovation, and arguments to the contrary must be contested wherever they abound.

Appendix: Methodology for Obtaining Financial Figures

Table 1: Spending by Manufacturers of Drugs Selected for Medicare Price Negotiation (in dollars)

Data was taken from the latest annual SEC filings for Fiscal Year 2022 of all U.S.-based companies. Advertising figures were taken from descriptive statements offered in these SEC filings.³⁰ Dividend and stock repurchase figures were taken from Consolidated Cash Flow Statements.³¹ For two companies, there was a discrepancy between descriptive statements as to share repurchases in the SEC filings versus information in the cash flow statements on the purchases of treasury stock.³² For consistency, this report uses the figures reported in the cash flow statements. Research and development figures were taken as reported in Consolidated Income/Earning Statements.³³ Foreign corporations AstraZeneca & Novartis filed Form 20-F with the SEC disclosing the instant data in similar formats, with the exception of advertising figures which do not appear to be descriptively reported.³⁴

Research and development, stock repurchase, and dividend figures for Novo Nordisk were obtained from publicly available Income and Cash Flow statements in annual reports.³⁵ A similar approach was used for Bayer AG, a German company: this data was taken from its publicly available annual report for 2022.³⁶

Executive compensation data was taken from the latest proxy statements filed with the SEC (Fiscal Year 2022) of all U.S.-based companies.³⁷ Figures on executive compensation were obtained from the Summary Compensation Table, which provides a total figure combining base salary, equity-based compensation, non-equity compensation according to the company's incentive plan, appreciation in pension value, deferred compensation, and "other compensation," which includes the cost of providing corporate travel, automobiles, and financial planning services.³⁸

³⁰ See e.g., AbbVie 2022 Form 10-K, at 57.

³¹ See e.g., AbbVie 2022 Form 10-K, at 54.

³² AbbVie describes that it repurchased \$1.1 billion in stocks for 2022, but its cash flow statement shows it expended \$1.487 billion on the purchase of treasury stock. Compare AbbVie 2022 Form 10-K, at 42 to AbbVie Form 10-K, at 54. Novartis described that it spent \$10.8 billion on share repurchases, but its cash flow statement shows that it spent \$10.652 billion on the acquisition of treasury stock. Compare Novartis 2022 Form 20-F, at 79 to Novartis 2022 Form 20-F, at F-5. These discrepancies do not affect the findings of this report.

³³ See e.g., AbbVie 2022 Form 10-K, at 50.

³⁴ AstraZeneca PLC, 2022 Form 20-F, at F-2, F-5, F-46 ("No share repurchases have been made since 2012"); Novartis, 2022 Form 20-F, at F-1, F-4,

³⁵ NOVO NORDISK, ANNUAL REPORT 2022 54-55 (2023).

³⁶ BAYER ANNUAL REPORT 2022 2, 87, 90-91, 150 (2023).

³⁷ See e.g., AbbVie, 2023 Proxy Statement, at 51.

³⁸ *Id.*

Foreign corporation AstraZeneca filed Form 20-F with the SEC, which incorporates by reference certain pages detailing remuneration from its annual report.³⁹ Novartis disclosed compensation figures for its Executive Committee in Form 20-F filed with the SEC.⁴⁰ Novo Nordisk disclosed executive compensation in its annual Remuneration Report.⁴¹ Bayer AG included its executive compensation figures in its annual report.⁴²

Data in foreign currencies were converted to U.S. dollars using the yearly average exchange rates for 2022 posted on the Internal Revenue Service's website.⁴³

Table 2: Executive Compensation for the Manufacturers of Drugs Selected for Medicare Price Negotiation (in dollars)

Executive compensation data was obtained using the approach outlined for Table 1. For U.S. based companies, stock-based and option-based awards were aggregated from the Summary Compensation Table to establish equity-based compensation for executives.⁴⁴ Foreign corporations often did not detail equity-based compensation in the same manner. They disclosed equity-based compensation in a category termed long-term incentive programs/awards.⁴⁵ Base salary was disclosed in a standard manner across companies.⁴⁶

Again, data in foreign currencies were converted to U.S. dollars using the yearly average exchange rates for 2022 posted on the Internal Revenue Service's website.⁴⁷

Table 3: Spending by the Manufacturers of the Costliest Drugs in Maryland (in dollars)

Research and development, stock buybacks, dividend payments, and total executive compensation figures were obtained using the same approach from Table 1. The following manufacturers of the drugs selected for Medicare price negotiation also appeared on the list of manufacturers of the 10 costliest drugs in Maryland: AbbVie, Bristol Myers Squibb, Pfizer, Eli Lilly, Johnson & Johnson, and Novo Nordisk. Therefore, the same data was used from Table 1.

³⁹ AstraZeneca, 2022 Form 20-F at 40; ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2022 111 (2023).

⁴⁰ Novartis, 2022 Form 20-F, at 105.

⁴¹ NOVO NORDISK, REMUNERATION REPORT 2022 12 (2023).

⁴² BAYER ANNUAL REPORT 2022 280-81 (2023).

⁴³ *Yearly Average Currency Exchange Rates*, IRS.GOV, <https://www.irs.gov/individuals/international-taxpayers/yearly-average-currency-exchange-rates> (last visited Jan. 8, 2023).

⁴⁴ *See e.g.*, AbbVie, 2023 Proxy Statement, at 51.

⁴⁵ ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2022 111 (2023); BAYER ANNUAL REPORT 2022 280-81 (2023); NOVO NORDISK, REMUNERATION REPORT 2022 12-14 (2023).

⁴⁶ *See e.g.*, AbbVie, 2023 Proxy Statement, at 51; ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2022 111 (2023); BAYER ANNUAL REPORT 2022 280-81 (2023); NOVO NORDISK, REMUNERATION REPORT 2022 12 (2023).

⁴⁷ *Yearly Average Currency Exchange Rates*, IRS.GOV, <https://www.irs.gov/individuals/international-taxpayers/yearly-average-currency-exchange-rates> (last visited Jan. 8, 2023).

Gilead and Biogen’s data on stock repurchases, dividends, and research and development figures were obtained from Consolidated Cash Flow Statements and Income/Earning Statements in their 2022 Form 10-K filing with the SEC.⁴⁸ Advertising figures for these companies were taken from the descriptive statements within these filings.⁴⁹ GSK filed Form 20-F with the SEC disclosing data on research and development, stock repurchases, and dividends.⁵⁰ Shionogi is a Japanese company that operates on a fiscal year from April 1, 2022, through March 31, 2023. To examine figures from 2022, data for research and development, stock repurchases, and dividends was taken from its third quarter report covering April 1, 2022, through December 31, 2022.⁵¹

Executive compensation figures for Gilead and Biogen were disclosed in their proxy statement filings with the SEC.⁵² For GSK, this data was obtained from its annual report incorporated by reference in its Form 20-F filing with the SEC.⁵³ Shionogi discloses executive compensation according to its fiscal calendar, so the latest disclosure covering Fiscal Year 2022 covered April 1, 2022, through March 31, 2023.⁵⁴

Data in foreign currencies were converted to U.S. dollars using the yearly average exchange rates for 2022 posted on the Internal Revenue Service’s website.⁵⁵

Table 4: Executive Compensation for the Manufacturers of the Costliest Drugs in Maryland (in dollars)

Executive compensation data was obtained using the approach outlined for Table 3. The following manufacturers of the drugs selected for Medicare price negotiation also appeared on the list of manufacturers of the 10 costliest drugs in Maryland, so their executive compensation figures from Table 2 were used: AbbVie, Bristol Myers Squibb, Pfizer, Eli Lilly, Johnson & Johnson, and Novo Nordisk.

Again, for U.S.-based companies, stock-based and option-based awards were aggregated to determine equity-based compensation for executives.⁵⁶ Equity-based compensation fell under the category of long-term incentive awards for GSK executives.⁵⁷ Shionogi disclosed

⁴⁸ See Gilead, 2022 Form 10-K, at 49, 52; Biogen 2022 Form 10-K, at F-2, F-5.

⁴⁹ See Gilead, 2022 Form 10-K, at 55; Biogen 2022 Form 10-K, at F-21.

⁵⁰ See GSK, 2022 Form 20-F, at 16, 34-35.

⁵¹ See SHIONOGI, CONSOLIDATED FINANCIAL RESULTS FOR THE THIRD QUARTER FISCAL YEAR 2022 (IFRS) 4,10 (Jan. 30, 2023).

⁵² See Gilead, Schedule 14A: 2023 Notice of Annual Meeting and Proxy Statement, at 69; Biogen, Schedule 14A: 2023 Annual Notice of Stockholders and Proxy Statement, at 56.

⁵³ See GSK, 2022 Form 20-F, at 51; GSK ANNUAL REPORT 2022 136 (2023).

⁵⁴ See Shionogi, *Chapter 3: Mechanisms Supporting SHIONOGI’s Growth*, from INTEGRATED REPORT 2023, at 93.

⁵⁵ *Yearly Average Currency Exchange Rates*, IRS.GOV, <https://www.irs.gov/individuals/international-taxpayers/yearly-average-currency-exchange-rates> (last visited Jan. 8, 2023).

⁵⁶ See Gilead, Schedule 14A: 2023 Notice of Annual Meeting and Proxy Statement, at 69; Biogen, Schedule 14A: 2023 Annual Notice of Stockholders and Proxy Statement, at 56.

⁵⁷ GSK ANNUAL REPORT 2022 136, 142 (2023).

stock-based compensation under a category termed “non-monetary remuneration.”⁵⁸ Base salary data was disclosed in a standard manner across companies.⁵⁹

Data in foreign currencies were converted to U.S. dollars using the yearly average exchange rates for 2022 posted on the Internal Revenue Service’s website.⁶⁰

⁵⁸ See Shionogi, *Chapter 3: Mechanisms Supporting SHIONOGI’s Growth*, from INTEGRATED REPORT 2023, at 93.

⁵⁹ Gilead, Schedule 14A: 2023 Notice of Annual Meeting and Proxy Statement, at 69; Biogen, Schedule 14A: 2023 Annual Notice of Stockholders and Proxy Statement, at 56; GSK ANNUAL REPORT 2022 136 (2023); Shionogi, *Chapter 3: Mechanisms Supporting SHIONOGI’s Growth*, from INTEGRATED REPORT 2023, at 93.

⁶⁰ *Yearly Average Currency Exchange Rates*, IRS.GOV, <https://www.irs.gov/individuals/international-taxpayers/yearly-average-currency-exchange-rates> (last visited Jan. 8, 2023).